Video

The Rationale for PARP Inhibition plus IO in Ovarian Cancer

Author(s):

Bradley J. Monk, MD, FACS, FACOG,Robert L. Coleman, MD, FACOG, FACS

Michael J. Birrer, MD, PhD, explains the reasoning for combining PARP inhibitors with immunotherapy in ovarian cancer treatment, highlighting ongoing trials.

Related Videos
Jennifer Scalici, MD
5 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Premal Thaker, MD, MS
Related Content
The OncFive: Top Oncology Articles for the Week of 11/10
November 16th 2024

The OncFive: Top Oncology Articles for the Week of 11/10

Vadim Gushchin, MD; Teresa Diaz-Montes, MD, MPH, FACOG
April 20th 2023

Gushchin and Diaz-Montes Describe QOL Outcomes After Cytoreduction and HIPEC in Ovarian Cancer

Ron Bentsur, chairman and CEO of Nuvectis Pharma
November 14th 2024

NXP800 Demonstrates Single-Agent Activity in ARID1a+ Platinum-Resistant Ovarian Cancer

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer
July 18th 2022

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer

BT7480 in Nectin-4+, CD137+ Tumors | Image Credit: © Katsyarina - stock.adobe.com
November 7th 2024

BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors

Ovarian Cancer | Image Credit: © magicmine - stock.adobe.com
November 3rd 2024

SHR-A1921 Demonstrates Early Efficacy in Platinum-Resistant Ovarian Cancer